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In one word, how would you describe your research? {#open201800065-sec-0001}
==================================================

![](OPEN-7-431-g002.jpg "image")"Transfer". As there is no stable nuclide of radium known, the main task of our research is focused on the development of chelating systems for barium and the transfer of these systems to the stable complexation of radium due to their similar chemical properties for preparation of α‐therapeutics. This is based on the synthesis of suitable functionalized calix\[4\]crowns, which serve as chelator for these heavy group 2 metals.

What are the main challenges in the broad area of your research? {#open201800065-sec-0002}
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We are confronted with two types of constraints. The first is related to a lack of suitable "cages" for the insertion of heavy group 2 metals, because of the coordination chemistry. The second originates from the strong recoil of during the alpha decay, which is higher as the energy value of chemical bonds. This leads to the development of "cages", which stably bind the metal ion without a release of the ion from this cage. Otherwise, the radium would not reach the desired tumor tissue and accumulate in the bones as classical "bone seeker" due to its chemical nature.

Furthermore, syntheses with α‐emitting radionuclides are challenging, owing to time and mass restrictions (nanomolar synthesis scale). Moreover, as high levels of radioactivity are manipulated, the automation of radiolabeling procedures is obligatory. Consequently, radiochemical methods with radium are still rather rare in comparison to the chemistry of the remaining group 2 metals used in conventional complex chemistry.
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Other projects are also associated with the formation of diagnostic and therapeutic radiotracers. On the one hand, we are using nanoparticles like polyoxometalates to stably bind radiometals. These particles will be further functionalized and serve as transporters for the radionuclides. On the other hand, we are using bioorthogonal methods like the traceless Staudinger Ligation or the copper‐catalyzed click chemistry to connect the radionuclide to the biologically or pharmacologically active compound under mild and physiological conditions. ![](OPEN-7-431-g001.jpg "image")
